BioMarin Pharmaceutical Inc. stock price

BioMarin Pharmaceutical Inc. latest news:


  • 02/22/2018 14:15:49

    BRIEF-BioMarin Q4 GAAP Loss Per Share $0.30

    BioMarin Pharmaceutical Inc(BMRN): * BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS. * Q4 GAAP LOSS PER SHARE $0.30. * QTRLY TOTAL REVENUES $358.3 MILLION VERSUS $300.1 MILLION. * SEES 2018 TOTAL REVENUES $1,470 MILLION TO $1,530 MILLION. * SEES 2018 GAAP NET LOSS OF $115 MILLION TO $165 MILLION. * SEES 2018 NON-GAAP INCOME OF $100 MILLION TO $140 MILLION.

  • 02/22/2018 12:31:26

    Earnings Reaction History: BioMarin Pharmaceutical, 33.3% Follow-Through Indicator, 2.1% Sensitive

    Expected Earnings Release: 02/22/2018, After-hours Avg. BioMarin Pharmaceutical (BMRN) is due to issue its quarterly earnings report in the upcoming extended-hours session.

  • 12/22/2017 06:31:46

    BRIEF-Biomarin Receives Anticipated Notification Of PDUFA Extension For Pegvaliase Biologics License Application

    Biomarin Pharmaceutical Inc(BMRN): * BIOMARIN RECEIVES ANTICIPATED NOTIFICATION OF PDUFA EXTENSION FOR PEGVALIASE BIOLOGICS LICENSE APPLICATION TO MAY 28, 2018 Source text for Eikon: Further company coverage:

  • More trends:

    BiondVax Pharmaceuticals Ltd.BVXV | BiondVax Pharmaceuticals Ltd.BVXVW | Bio-Path Holdings, Inc.BPTH | BioScrip, Inc.BIOS | BioShares Biotechnology Clinical Trials FundBBC | BioShares Biotechnology Products FundBBP | BioSpecifics Technologies CorpBSTC | Biostar Pharmaceuticals, Inc.BSPM | Biota Pharmaceuticals, Inc.BOTA | Bio-Techne CorpTECH |